CJC/IPA Protocol (CJC-1295/Ipamorelin): Research Overview

What is CJC/IPA Protocol?

A dual-pathway protocol combining CJC-1295 and Ipamorelin that targets growth hormone secretion through complementary mechanisms. CJC-1295 demonstrates 2-10 fold GH increases with 6-8 day duration, while Ipamorelin provides selective GH release without cortisol elevation.

What is CJC/IPA Protocol researched for?

• Growth hormone elevation supports muscle protein synthesis and nitrogen retention during training.
• Sustained GH patterns may accelerate muscle repair between exercise sessions.
• GH optimization helps maintain muscle during caloric restriction or aging.
• Growth hormone promotes lipolysis while supporting lean tissue maintenance.
• Enhanced GH patterns may improve glucose and fat utilization.
• Evening GH peaks align with deeper, more restorative sleep patterns.
• Sustained GH elevation supports skin elasticity and connective tissue health.
• Growth hormone supports tissue repair and recovery from exercise or injury.
• Enhanced collagen synthesis supports joint and connective tissue integrity.

How does CJC/IPA Protocol work?

CJC-1295 activates GHRH receptors via albumin-binding DAC technology for sustained elevation. Ipamorelin selectively activates ghrelin receptors (GHSR1a) without affecting ACTH/cortisol, preserving natural pulsatile GH patterns.

Reported targets: GHSR1a, GHRH receptor, ghrelin receptor

References

1. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults

   Teichman SL, Neale A, Lawrence B, et al. · The Journal of clinical endocrinology and metabolism · 2006

   Single CJC-1295 injection produced dose-dependent 2-10 fold GH increases for 6+ days and 1.5-3 fold IGF-1 increases for 9-11 days; estimated half-life 5.8-8.1 days.

   Early human study · PMID 16352683

2. Ipamorelin, the first selective growth hormone secretagogue

   Raun K, Hansen BS, Johansen NL, et al. · European journal of endocrinology · 1998

   Ipamorelin is the first GHRP-receptor agonist with selectivity for GH release similar to GHRH; does not release ACTH or cortisol even at doses over 200-fold the ED50 for GH.

   PMID 9849822

3. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog

   Ionescu M, Frohman LA · The Journal of clinical endocrinology and metabolism · 2006

   CJC-1295 preserves pulsatile GH secretion with unaltered pulse frequency and magnitude; basal GH levels increased 7.5-fold, mean GH 46%, and IGF-1 45%.

   PMID 17018654

4. Ghrelin and growth hormone secretagogues potentiate GH-releasing hormone-induced cAMP production in cells expressing transfected GHRH and GH secretagogue receptors Cunha SR, Mayo KE Endocrinology

   2002

   GHS potentiate GHRH-induced cAMP in a dose-dependent manner requiring co-expression of both receptors, providing the cellular basis for GHRH/GHRP synergy.

5. Ghrelin and growth hormone (GH) secretagogues potentiate GH-releasing hormone (GHRH)-induced cyclic adenosine 3',5'-monophosphate production in cells expressing transfected GHRH and GH secretagogue receptors

   Cunha SR, Mayo KE · Endocrinology · 2002

   PMID 12446584

Common questions